Approved Study Database

Ref. No. Scientific Title Principal investigator
2009.522 Characterization of Epstein-Barr virus induced genetic and epigenetic alterations in cholangiocarcinoma cells Prof To Ka Fai
2009.521 Characterization of YAPI as a function oncogene in gastric cancer Prof To Ka Fai
2012.020 Detection of Oncogenic Driver Mutation in Non-small Cell Lung Cancer Prof To Ka Fai
2014.315 The effect of educational-based adherence intervention on adherence of inhalation therapy, disease control, quality of life and healthcare utilization among patients with chronic obstructive pulmonary disease: a randomized controlled trial, pilot study Ms To Ka Wing
2014.143 Establishment of a primary cell culture platform of human solid cancers to facilitate molecular and functional studies Prof To Ka-Fai
2009.562 MicroRNA-mediated regulation of the multidrug resistance transporter ABCG2 Professor To Kin Wah
2012.079 Epigenetic downregulation of the xenobiotic transporter ABCG2 as a predisposing factor for diet-induced colorectal cancer development Professor To Kin Wah
2012.064 Epigenetic down-regulation of the xenobiotic transporter ACG2 - a predisposing factor for colorectal cancer development and a novel target for cancer prevention? Professor To Kin Wah
2010.254 Prognostic value of ABCG2 and its modulation by microRNAs in AML Professor To Kin Wah
2013.161 Xenobiotic transporter ABCG2: Regulatory role in the initiation and progression of colorectal cancer Professor To Kin Wah
2010.398 Novel prognostic markers for predicting response to chemotherapy in colorectal cancer Professor To Kin Wah
2011.034 Exploiting regulation of the drug transporter ABCG2 for personalized treatment with the HMG-CoA reductase inhibitors (Statins) Prof To Kin Wah
2011.155 Novel prognostic biomarkers for predicting response to chemotherapy in colorectal cancer Professor To Kin Wah
2010.034 Clinical relevance of microRNA dysregulation and DNA methylation in mediating overexpression of ABCG2 in chemo-resistant colorectal cancer Professor To Kin Wah
2012.037 Comparison of Nasal Positive End Expiratory Pressure valve to dental device as an alternative treatment for OSA Dr. To Kin Wang
2008.193 A Cross Sectional Study of Prevalence of Sleep Disordered Breathing in Patients on HAART in a HIV Clinic in Hong Kong Dr To Kin Wang
2013.689 A cross over case control study using a vibration positional device for treatment of position dependent obstructive sleep apnea Dr. TO Kin Wang
2016.737 Mortality among Tuberculosis patients in Hong Kong Dr. TO Kin Wang
杜建宏
2014.556 Application of GeneXpert on bronchoscopic samples in the clinical management of patients suspicious of Tuberculosis Dr. TO Kin Wang
2016.661 Validation of a novel device for screening patients with symptoms of obstructive sleep apnea Dr. TO Kin Wang
杜建宏
2019.025 A validation study of a portable monitoring device for diagnosing obstructive sleep apnea in patients with co-existing medical illnesses Dr. TO Kin Wang
2020.034 Prospective study to evaluate Stretococcus pneumoniae serotype prevalence in community acquired pneumonia in Hong Kong using a urinary kit Dr. TO Kin Wang
杜建宏
2018.478 Situation of idiopathic pulmonary fibrosis in Hong Kong --- a 5 year retrospective epidemiology study Dr. TO Kin Wang
杜建宏
2018.159 Endoscopic retrograde cholangiopancreatography (ERCP) in older patients: is age a risk factor for complications? Dr. TO Tsz Yan
杜芷茵
2022.354 An investigation of air dispersion pattern and the environmental influence of open airway suction in general ward setting and identification of a practical enclosure device for open airway suction in general ward. Ms. TO YUK LING
杜玉玲
2021.127 The effect of culturally-adapted music therapy on preoperative anxiety, acute postoperative pain and haemodynamic readings among women with breast cancer receiving mastectomy in Nigeria: A randomised controlled trial Ms. TOLA Yetunde Oluwafunmilayo
2011.473 Effect of a multi-herb product on plasma lipids levels in Chinese patients with dyslipidaemia Prof Tomlinson Brian
2008.572 The combined effects of drug transporter pharmacogenetics and drug interactions on the pharmacokinetics of statins in Chinese subjects-Simvastatin pharmacokinetic study Professor Tomlinson Brian
2011.002 Does the plasma Cholesterol level Affect the Expression of drug Transporters? Prof Tomlinson Brian
2011.341 A Single-Dose, Randomized, Double-Blind, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Adult Healthy Volunteers Professor Tomlinson Brian
2012.340 Retrospective case review of patients during diagnosed as having rhabdomyolysis in the Prince of Wales Hospital Prof. TOMLINSON Brian
2011.472 Pharmacogenomics of Niacin in Patients with Erectile Dysfunction and Dyslipidaemia - a Follow-on Study Prof Tomlinson Brian
2013.676 Investigation of cases of drug/chemical toxicity, adverse drug reactions and interactions Prof. TOMLINSON Brian
2008.151 Investigation on the Pharmacogenetics of Medications Used in Pharmacokinetic Trials MD Tomlinson Brian
2009.156 Prevalence, Treatment Patterns & Resource Use in Patients with Mixed Dyslipidemia Using Lipid Lowering Agents Prof Tomlinson Brian
2015.448 Retrospective pharmacogenetic analysis of dose requirement in patients on long-term stable warfarin treatment Prof. TOMLINSON Brian
湯寧信醫生
2015.429 Cost effectiveness of Dapagliflozin for the treatment of Type 2 Diabetes Mellitus in Hong Kong Prof. TOMLINSON Brian
湯寧信醫生
2015.115 The impact of Illness Representations on illness management in patients with Familial Hypercholesterolemia Prof. TOMLINSON Brian
湯寧信
2014.516 Comparison of serum thromboxane B2 and platelet function testing with the Multiplate® device as measures of aspirin resistance in Hong Kong Chinese patients with increased cardiovascular risk with stable coronary heart disease or peripheral artery disease Prof. TOMLINSON Brian
2015.116 Health care resource utilization analysis of paliperidone palmitate in the treatment of schizophrenia in the public health care sector of Hong Kong Prof. TOMLINSON Brian
湯寧信醫生
2010.600 An Open Label, Randomized, Cross-Over Study to Investigate the Single Dose Bioequivalence of Lamotrigine Dispersible/Chewable Tablets (5mg) Compared to Lamotrigine Compressed/Standard Tablets (25mg) in Chinese Healthy Male Subjects. Professor Tomlinson Brian
2012.331 A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease Professor Tomlinson Brian
2008.503 Predictors of Antihypertensive Response to Bisoprolol and Hydrocholorothiazide: An Open-labelled, Placebo-controlled Crossover Study to Investigate the Genetic and Biomedical Predictors of Blood Pressure Response in Chinese Patients with Mild to Moderate Hypertension Professor Tomlinson Brian
2011.521 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Continuation Period to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients with Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol Prof. TOMLINSON Brian
2008.302 Randomized Cross-Over Clinical Bioequivalence Study on Two Oral Lithium Carbonate Formulations Prof Tomlinson Brian
2010.399 Phase I, open label, randomized study to examine the pharmacokinetics, safety and tolerability of different oral doses of TMC435 after single and repeated dosing in healthy Chinese subjects Prof. Tomlinson Brian
2013.052 Pharmacogenomics of anti-hypertensive treatment in Chinese, from unpredictable response to personalized medicine Prof Tomlinson Brian
2010.200 A Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy Prof. Tomlinson Brian
2008.153 A 2 year extension to: A 76-week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy with a Statin in Patients with Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease: Reversal period extended from 12 weeks to 1-year Professor Tomlinson Brian
2012.330 A randomized, double-blind, crossover study to assess the effects of LCZ696 and valsartan in Asian patients with salt-sensitive hypertension Prof. Tomlinson Brian

Page 212 of 265.